"Unreasonable" foreign pharma investment prompts Indian call for policy review
This article was originally published in Scrip
Executive Summary
The debate on the need to review foreign direct investment (FDI) norms in the Indian pharmaceutical sector is set to reach a new crescendo, with domestic firms building their case against a freer regime with data suggesting that foreign companies have not made substantial investments in fixed assets or R&D in the country over a 15-year period.